GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA,
GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA, which has shown potential in diagnosing Parkinson's disease. The new technology, part of GE's PETtrace cyclotron offering, evolved from a collaboration with Imanet, a joint venture between Amersham and leading PET research centers. The 18F-F2 option boosts production capacity by nearly a factor of four, according to GE. This will increase the availability of this compound for use in research while laying the groundwork for wider use if F-DOPA becomes clinically viable.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.